ASH: With Yescar­ta lead­ing in ear­li­er-line lym­phoma, Bris­tol My­ers keeps the heat on with full da­ta for Breyanzi

Kick­ing off this week­end’s #ASH21, Gilead’s Kite and Bris­tol My­ers Squibb have re­leased com­pet­ing da­ta for their cur­rent-gen CAR-T drugs in sec­ond-line B cell lym­phoma pa­tients. It’s a heat­ed con­test to move these drugs in­to ear­li­er lines of ther­a­py, and Bris­tol My­ers thinks these fuller da­ta will keep the pres­sure on.

Bris­tol My­ers’ Breyanzi (liso­cab­ta­gene mar­aleu­cel) cut the risk of dis­ease pro­gres­sion, death and oth­er events by 65% over stan­dard of care in sec­ond-line re­lapsed or re­frac­to­ry LB­CL pa­tients, ac­cord­ing to da­ta from the Phase III TRANS­FORM study pre­sent­ed Sat­ur­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER